Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases.
about
Bronchodilators for bronchiolitisGlucocorticoids for acute viral bronchiolitis in infants and young childrenGlucocorticoids for acute viral bronchiolitis in infants and young childrenRationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virusSocial, economic, and health impact of the respiratory syncytial virus: a systematic searchThe use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infectionBiomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severityDefining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western CountriesAssociating Changes in the Immune System with Clinical Diseases for Interpretation in Risk AssessmentRespiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysisInterferon induction and function at the mucosal surface.A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.Modeling the variations in pediatric respiratory syncytial virus seasonal epidemicsCosts of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010.Respiratory syncytial virus infections in infants affected by primary immunodeficiency.Limited type I interferons and plasmacytoid dendritic cells during neonatal respiratory syncytial virus infection permit immunopathogenesis upon reinfection.Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vectorA cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virusThe use of a neonatal mouse model to study respiratory syncytial virus infections.A high-throughput screening strategy to overcome virus instabilityPartial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.Cost of illness of hyponatremia in the United States.Comparison of risk factors between preterm and term infants hospitalized for severe respiratory syncytial virus in the Russian Federation.Animal models of human respiratory syncytial virus diseaseNeonatal CD8 T-cell hierarchy is distinct from adults and is influenced by intrinsic T cell properties in respiratory syncytial virus infected mice.Resveratrol-mediated gamma interferon reduction prevents airway inflammation and airway hyperresponsiveness in respiratory syncytial virus-infected immunocompromised mice.A Phenotypic High-Throughput Screen with RSV-Infected Primary Human Small Airway Epithelial Cells (SAECs).Immunological, Viral, Environmental, and Individual Factors Modulating Lung Immune Response to Respiratory Syncytial Virus.Reduced inflammation and altered innate response in neonates during paramyxoviral infectionAntisense approaches for inhibiting respiratory syncytial virus.Differential type I interferon induction by respiratory syncytial virus and influenza a virus in vivo.Influenza and respiratory syncytial viruses: Efficacy of different diagnostic assays.Cross-immunity between strains explains the dynamical pattern of paramyxovirusesRespiratory syncytial virus: diagnosis, treatment and preventionComparison of Cepheid's analyte-specific reagents with BD directigen for detection of respiratory syncytial virusRespiratory syncytial virus persistence in the lungs correlates with airway hyperreactivity in the mouse model.Respiratory syncytial virus (RSV) suppression of glucocorticoid receptor phosphorylation does not account for repression of transactivationEmerging drugs for respiratory syncytial virus infection.
P2860
Q24193936-BF8BE8DB-B1DF-4D95-A3FB-80188D4B40D2Q24202303-7CDFF0C4-3FCA-4FCA-875E-0D14F2BE4DA5Q24234702-8A5C389C-90B1-415A-A7EF-A705F64F82FCQ26825438-E70FCD8F-D323-43B3-AD58-CBACD203F197Q26852865-16E44D63-5FBA-42E1-85A4-401816E48A76Q26864494-C2AC401A-BE84-4F4A-BB04-225A8A1085DDQ27010165-6FECA54D-7D02-4B72-BF0C-45BB3307255FQ28069415-4E5843B8-F9F1-4490-943E-8DBA3C0F51A2Q28388987-311A6380-E763-4D1F-BF0F-1789F0F74438Q30240274-511A7C96-48C6-4108-A05E-B01897458099Q30244591-326AB702-176C-4550-A5F1-5A584C8A2961Q30661545-7F669EF0-B914-47F6-B98B-4DECB041C1AEQ33595073-4F1603BE-FD9A-4476-8E96-F8C1EAE80CE7Q33630047-4F19E97C-29C7-47CD-B018-BC2F5C0CF41DQ33879075-59F0F4B2-07BE-4375-9979-DBEC6A3DEAE9Q33887198-16E17B60-B183-4677-8CAE-3CF86E3D5FD8Q33892605-692B54B2-C844-4ECD-AA06-F779663FA199Q34059301-CAE5A372-243A-4BD5-83CF-15F908F719CAQ34302198-84C2A3EE-81E5-4428-87D0-D7CF09778FF9Q34542805-DDF8D099-2FD0-4FB3-8AB7-2B698C360A85Q34549253-214347BB-B7A2-4C14-9D49-32AE334B93B8Q34729728-1D5A6EC3-7D37-4BDF-B2A6-D6AA3E882655Q34875961-668C7AE9-90AC-4802-B554-B1231B8BDE7DQ34885683-E93DAFB4-A528-4B68-8996-88C5059568CAQ35119631-CCF59EFF-7FA5-4870-87AB-98D5C420B1AAQ35159747-3C34A0BE-D472-48E6-A15B-4DB84C41F778Q35586896-C8A1D309-ED78-4D99-BC9A-F8629AC56417Q35599372-6C62ED68-C4FF-445A-82C1-991EFCCFFB29Q35599468-6574D778-0F02-408F-A4D9-E645FBA2C95AQ35625850-408942CA-96A1-46AD-8D29-23754A1ECE47Q35766500-80165613-8673-4453-976F-343AE49821C5Q36065956-21AA3678-9ACA-4251-8BB7-FDC902A85539Q36098849-108DF1AD-C8F2-43D9-B031-979BA579D7E1Q36111168-34B600FE-FB48-45D9-87DC-00CCE3CCB849Q36238328-4CDBA771-2FBB-4A4D-9D19-F5E55DE44644Q36290495-27DE1D70-3FAF-4BDE-BB29-BCDE3D1ED04FQ36689615-3CBA5A28-7C1F-4237-9858-E2C3DBD2E967Q36946801-671B7CEF-ED92-4ABD-99B0-139BD92064B7Q37090985-D5C30F5D-6C2B-40C5-ACA4-88FACAC15AB2Q37250650-F9B6AB67-AB10-4B81-9019-D0A53C6D9A65
P2860
Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Economic impact of respiratory ...... nalysis of national databases.
@en
Economic impact of respiratory ...... nalysis of national databases.
@nl
type
label
Economic impact of respiratory ...... nalysis of national databases.
@en
Economic impact of respiratory ...... nalysis of national databases.
@nl
prefLabel
Economic impact of respiratory ...... nalysis of national databases.
@en
Economic impact of respiratory ...... nalysis of national databases.
@nl
P2093
P1433
P1476
Economic impact of respiratory ...... nalysis of national databases.
@en
P2093
Gabrielle Ciesla
L Clark Paramore
Vincent Ciuryla
P304
P356
10.2165/00019053-200422050-00001
P577
2004-01-01T00:00:00Z
P6179
1000768368